| Outcome Measures: |
Primary: HbA1c Change From Baseline to Week 24, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin., Baseline and week 24 | Secondary: HbA1c Change From Baseline to Week 6, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 6 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin., Baseline and week 6|HbA1c Change From Baseline to Week 12, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin., Baseline and week 12|HbA1c Change From Baseline to Week 18, HbA1c is measured as a percentage. Thus, this change from baseline reflects the Week 18 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and prior use of insulin., Baseline and week 18|FPG Change From Baseline to Week 24, This change from baseline reflects the Week 24 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin., Baseline and week 24|FPG Change From Baseline to Week 6, This change from baseline reflects the Week 6 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction., Baseline and week 6|FPG Change From Baseline to Week 12, This change from baseline reflects the Week 12 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction., Baseline and week 12|FPG Change From Baseline to Week 18, This change from baseline reflects the Week 18 FPG minus the baseline FPG. Means are treatment-adjusted for baseline HbA1c, baseline FPG and prior use of insulin, week repeated within patient and week by treatment interaction., Baseline and week 18|Percentage of Patients With HbA1c <7.0% at Week 24, The percentage of patients with an HbA1c value below 7% at week 24 was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%. Only patients with baseline HbA1c \>= 7%, Baseline and week 24|Percentage of Patients With HbA1c <7.0% at Week 24, The percentage of patients with an HbA1c value below 7% at week 24 were calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c above 7%., Baseline and week 24|Percentage of Patients Who Have a HbA1c Lowering by at Least 0.5% at Week 24, The percentage of patients with an HbA1c reduction of ≥0.5% at week 24 from baseline was calculated for each treatment arm. If a patient did not have an HbA1c value at week 24 they were considered a failure, so HbA1c reduction less than 0.5%, Baseline and week 24|Number of Patients With Rescue Therapy, The use of rescue therapy was planned for patients failing to achieve preset criteria based on glucose levels during the randomised treatment period of the trial, week 24
|
| Locations: |
1218.63.61005 Boehringer Ingelheim Investigational Site, Gosford, New South Wales, Australia|1218.63.61006 Boehringer Ingelheim Investigational Site, Herston, Queensland, Australia|1218.63.61003 Boehringer Ingelheim Investigational Site, Adelaide, South Australia, Australia|1218.63.61002 Boehringer Ingelheim Investigational Site, Daw Park, South Australia, Australia|1218.63.61007 Boehringer Ingelheim Investigational Site, East Ringwood, Victoria, Australia|1218.63.61001 Boehringer Ingelheim Investigational Site, Parkville, Victoria, Australia|1218.63.61004 Boehringer Ingelheim Investigational Site, Reservoir, Victoria, Australia|1218.63.10008 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1218.63.10003 Boehringer Ingelheim Investigational Site, Hamilton, Ontario, Canada|1218.63.10005 Boehringer Ingelheim Investigational Site, Hawkesbury, Ontario, Canada|1218.63.10007 Boehringer Ingelheim Investigational Site, Newmarket, Ontario, Canada|1218.63.10006 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1218.63.10001 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1218.63.10002 Boehringer Ingelheim Investigational Site, St-Romuald, Quebec, Canada|1218.63.10004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada|1218.63.45007 Boehringer Ingelheim Investigational Site, Aalborg, Denmark|1218.63.45002 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|1218.63.45003 Boehringer Ingelheim Investigational Site, Aarhus C, Denmark|1218.63.45001 Boehringer Ingelheim Investigational Site, Birkerød, Denmark|1218.63.45008 Boehringer Ingelheim Investigational Site, Hellerup, Denmark|1218.63.45006 Boehringer Ingelheim Investigational Site, Hillerød, Denmark|1218.63.45004 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark|1218.63.45005 Bispebjerg Hospital, København NV, Denmark|1218.63.31008 Boehringer Ingelheim Investigational Site, Beek en Donk, Netherlands|1218.63.31007 Boehringer Ingelheim Investigational Site, Beerzerveld, Netherlands|1218.63.31012 Boehringer Ingelheim Investigational Site, Doetinchem, Netherlands|1218.63.31014 Boehringer Ingelheim Investigational Site, Etten-Leur, Netherlands|1218.63.31009 Boehringer Ingelheim Investigational Site, Oude Pekela, Netherlands|1218.63.31001 Boehringer Ingelheim Investigational Site, Tubbergen, Netherlands|1218.63.46004 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1218.63.46003 Boehringer Ingelheim Investigational Site, Järfälla, Sweden|1218.63.46001 Boehringer Ingelheim Investigational Site, Malmö, Sweden|1218.63.46002 Boehringer Ingelheim Investigational Site, Sundsvall, Sweden|1218.63.46005 Boehringer Ingelheim Investigational Site, Uppsala, Sweden
|
